STTT：卓扬佳/钟惟德/何慧婵团队开发化疗-光热协同疗法，诱导铁死亡，促进抗肿瘤免疫并预防复发

Core Viewpoint - The research presents a novel tumor-targeting nanoplatform that enhances the efficacy of the chemotherapy drug Docetaxel through a combination of photothermal and photodynamic therapy, inducing ferroptosis and promoting a robust anti-tumor immune response [2][6]. Group 1 - The study developed a biocompatible polymer PPEGMA-b-PFMMA (PF) for co-encapsulating Docetaxel and the photosensitizer IR808, forming photothermal-responsive nanoparticles (P8D NP) [4]. - P8D NP utilizes hydrogen peroxide (H₂O₂) in the tumor microenvironment to trigger drug release, significantly improving the solubility and tumor-specific accumulation of both drugs [4]. - Under near-infrared (NIR) laser irradiation, P8D NP generates heat and reactive oxygen species (ROS), facilitating the disintegration of nanoparticles and drug release [4]. Group 2 - Mechanistically, Docetaxel induces the translocation of HMGB1 from the nucleus to the cytoplasm, while photothermal/photodynamic therapy promotes the release of damage-associated molecular patterns (DAMP) and tumor-associated antigens [6]. - These actions enhance the maturation of dendritic cells (DC), antigen presentation, and infiltration of cytotoxic CD8⁺ T cells into the tumor, effectively reversing the immunosuppressive tumor microenvironment [6]. - The combined treatment strategy not only inhibits the growth of distant tumors but also establishes long-term anti-tumor immune memory, preventing tumor recurrence [6].